HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Firm's Supplement Claims For Hangover Relief Watered Down In Industry Self-Regulation Review

Executive Summary

More Labs’ online claims might not be distilled satisfactorily for FDA’s taste for dietary supplement claims for hangover help agency made known a year ago. Firm will narrow claim suggesting its products could broadly relieve hangover symptoms.

You may also be interested in...



Hangover Supplement Marketer Tries Again, Targeting Main Causes Of Symptoms

Tomo Labs launches namesake brand supplement containing ingredients targeting the three main causes of hangover symptoms. Currently selling online, it hopes to introduce Tomo in groceries, pharmacies and liquor stores.

‘OMUFA Fee Liable’ Trending In US OTC Drug Industry To Pay For FDA's Monograph Reform

Some firms with sales in nonprescription drug space are exempt from program’s facility fees, but own-label OTC drug marketers aren’t among them. Although FDA allows fee discounts for small businesses in other areas, it’s not trimming monograph user fee rates.

Widely Available Unapproved Hangover Remedies Concern US FDA As Encouraging Overindulgence

As CFSAN warned seven marketers, supplement products from numerous other businesses advertised as hangover remedies, or as formulations to prevent symptoms associated with overindulgence, remained available to US consumers. Like one business FDA warned, numerous companies are offering OTC intravenous treatments for hangovers, available at locations accepting walk-in or by-appointment customers.

Related Content

Topics

UsernamePublicRestriction

Register

RS151595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel